Loading
Talazoparib helped some people with advanced cancers carrying tumour-only BRCA mutations. The study was small and included several cancer types.
Phase 2 molecular basket, median four prior lines of therapy. Cohorts included somatic BRCA1/2, other homologous-recombination repair genes, PTEN and germline BRCA1/2 in cancers outside breast/ovarian indications. Clinical benefit included response or stable disease lasting at least 24 weeks.
Mixed, heavily pretreated cancers and no control arm; cannot compare its ORR directly with olaparib trials or establish postoperative benefit.
Shares Talazoparib, PARP, Breast cancer (all types).
Shares PARP, Breast cancer (all types), Triple-negative breast cancer (TNBC).
Shares Talazoparib, PARP, Triple-negative breast cancer (TNBC).
Shares PARP, Breast cancer (all types), Triple-negative breast cancer (TNBC).
Shares PARP, Breast cancer (all types), Triple-negative breast cancer (TNBC).
Shares PARP, Breast cancer (all types).
Shares PARP, Breast cancer (all types).
Shares PARP, Breast cancer (all types), Triple-negative breast cancer (TNBC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/